Sotorasib dosing and incremental cost ineffectiveness — implications and lessons for stakeholders

Nature Reviews Clinical Oncology, Published online: 30 January 2024; doi:10.1038/s41571-024-00862-6The US FDA Accelerated Approval of sotorasib required the sponsor to conduct a randomized trial that compared the safety and efficacy of the approved dose with a lower dose. These results, recently disclosed, have important implications for patients, payers, oncologists and the pharmaceutical industry.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research